Table 2.
BCL11A | BCL11A_XL | BCL11A_L | BCL11A_S | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Down | Up | p-value | Down | Up | p-value | Down | Up | p-value | Down | Up | p-value | |
Age at diagnosis (years) | ||||||||||||
≤ 50 | 15 (31.9) | 7 (50.0) | 0.22 | 12 (32.4) | 9 (40.9) | 0.51 | 10 (28.6) | 8 (50.0) | 0.14 | 14 (33.3) | 4 (66.7) | 0.18 |
> 50 | 32 (68.1) | 7 (50.0) | 25 (67.6) | 13 (59.1) | 25 (71.4) | 8 (50.0) | 28 (66.7) | 2 (33.3) | ||||
Menstrual Status | ||||||||||||
Yes, physiological | 11 (50.0) | 2 (33.3) | 0.83 | 9 (47.4) | 3 (37.5) | 0.85 | 8 (44.4) | 2 (40.0) | 0.98 | 10 (47.6) | 0 (0.0) | 0.31 |
Yes, post-surgical | 3 (13.6) | 1 (16.7) | 3 (15.8) | 1 (12.5) | 3 (16.7) | 1 (20.0) | 4 (19.1) | 0 (0.0) | ||||
No | 8 (36.4) | 3 (50.0) | 7 (36.8) | 4 (50.0) | 7 (38.9) | 2 (40.0) | 7 (33.3) | 2 (100.0) | ||||
Site | ||||||||||||
Right | 21 (47.7) | 10 (71.4) | 0.41 | 18 (52.9) | 12 (54.6) | 1.00 | 16 (48.5) | 9 (56.3) | 0.72 | 17 (42.5) | 5 (83.3) | 0.21 |
Left | 22 (50.0) | 4 (28.6) | 15 (44.1) | 10 (45.5) | 16 (48.5) | 9 (56.3) | 22 (55.0) | 1 (16.7) | ||||
Bilateral | 1 (2.3) | 0 (0.0) | 1 (2.9) | 0 (0.0) | 1 (3.0) | 0 (0.0) | 1 (2.5) | 0 (0.0) | ||||
Histological subtype | ||||||||||||
Invasive ductal carcinoma (NST) | 32 (68.1) | 8 (57.1) | 0.80 | 27 (73.0) | 13 (59.1) | 0.36 | 27 (77.1) | 7 (43.8) | 0.04 | 29 (69.1) | 2 (33.3) | 0.17 |
Medullary carcinoma | 6 (12.8) | 3 (21.4) | 3 (8.1) | 5 (22.7) | 3 (8.6) | 4 (25.0) | 5 (11.9) | 2 (33.3) | ||||
Metaplastic carcinoma | 3 (6.4) | 1 (7.1) | 2 (5.4) | 2 (9.1) | 1 (2.9) | 3 (18.8) | 3 (7.1) | 1 (16.7) | ||||
Other | 6 (12.8) | 2 (14.3) | 5 (13.5) | 2 (9.1) | 4 (11.4) | 2 (12.5) | 5 (11.9) | 1 (16.7) | ||||
Tumor size (cm) | ||||||||||||
≤ 20 mm | 26 (55.3) | 8 (57.1) | 0.90 | 19 (51.4) | 13 (59.1) | 0.56 | 18 (51.4) | 10 (62.5) | 0.46 | 24 (57.19 | 3 (50.0) | 1.00 |
> 20 mm | 21 (44.7) | 6 (42.9) | 18 (48.7) | 9 (40.9) | 17 (48.6) | 6 (37.5) | 18 (42.9) | 3 (50.0) | ||||
Histologic grade | ||||||||||||
G1 | 1 (2.1) | 2 (14.3) | 0.20 | 1 (2.7) | 2 (9.1) | 0.38 | 1 (2.9) | 2 (12.5) | 0.28 | 2 (4.8) | 1 (16.7) | 0.25 |
G2 | 7 (14.9) | 1 (7.1) | 4 (10.8) | 4 (18.2) | 5 (14.3) | 3 (18.8) | 8 (19.1) | 0 (0.0) | ||||
G3 | 39 (83.0) | 11 (78.6) | 32 (86.5) | 16 (72.7) | 29 (82.9) | 11 (68.8) | 32 (76.2) | 5 (83.3) | ||||
Pathologic tumor classification | ||||||||||||
pT1 | 17 (38.6) | 7 (58.3) | 0.65 | 11 (32.4) | 11 (55.0) | 0.20 | 11 (35.5) | 8 (53.3) | 0.39 | 16 (42.1) | 2 (40.0) | 1.00 |
pT2 | 21 (47.7) | 5 (41.7) | 17 (50.0) | 9 (45.0) | 14 (45.2) | 7 (46.7) | 17 (44.7) | 3 (60.0) | ||||
pT3 | 3 (6.8) | 0 (0.0) | 3 (8.8) | 0 (0.0) | 3 (9.7) | 0 (0.0) | 3 (7.9) | 0 (0.0) | ||||
pT4 | 3 (6.8) | 0 (0.0) | 3 (8.8) | 0 (0.0) | 3 (9.7) | 0 (0.0) | 2 (5.3) | 0 (0.0) | ||||
Regional lymph nodes involvement | ||||||||||||
pN0 | 23 (52.3) | 8 (57.1) | 0.68 | 16 (45.7) | 13 (61.9) | 0.33 | 14 (42.4) | 8 (53.3) | 0.44 | 18 (46.2) | 3 (50.0) | 0.84 |
pN1 | 11 (25.0) | 5 (35.7) | 10 (28.6) | 6 (28.6) | 10 (30.3) | 6 (40.0) | 12 (30.8) | 3 (50.0) | ||||
pN2 | 5 (11.4) | 1 (7.1) | 4 (11.4) | 2 (9.5) | 4 (12.1) | 1 (6.7) | 5 (12.8) | 0 (0.0) | ||||
pN3 | 5 (11.4) | 0 (0.0) | 5 (14.3) | 0 (0.0) | 5 (15.2) | 0 (0.0) | 4 (10.3) | 0 (0.0) | ||||
Tumor stage | ||||||||||||
I | 10 (23.8) | 3 (25.0) | 0.46 | 5 (15.2) | 6 (31.6) | 0.18 | 6 (20.0) | 3 (21.4) | 0.18 | 8 (22.2) | 0 (0.0) | 0.21 |
II | 21 (50.0) | 8 (66.7) | 18 (54.6) | 11 (57.9) | 14 (46.7) | 10 (71.49 | 18 (50.0) | 5 (100.0) | ||||
III | 11 (26.2) | 1 (8.3) | 10 (30.3) | 2 (10.5) | 10 (33.3) | 1 (7.1) | 10 (27.8) | 0 (0.0) | ||||
Necrosis | ||||||||||||
Present | 16 (37.2) | 4 (28.6) | 0.75 | 15 (44.1) | 5 (22.7) | 0.10 | 12 (36.4) | 4 (25.0) | 0.53 | 13 (32.5) | 2 (33.3) | 1.00 |
Absent | 27 (62.8) | 10 (71.4) | 19 (55.9) | 17 (77.3) | 21 (63.6) | 12 (75.0) | 27 (67.5) | 4 (66.7) | ||||
Tumor infiltrating lymphocytes | ||||||||||||
Present | 20 (52.6) | 7 (53.9) | 1.00 | 15 (51.7) | 11 (52.4) | 1.00 | 13 (46.4) | 8 (53.3) | 0.76 | 16 (44.4) | 4 (80.0) | 0.18 |
Absent | 18 (47.4) | 6 (46.2) | 14 (48.3) | 10 (47.6) | 15 (53.6) | 7 (46.7) | 20 (55.6) | 1 (20.0) | ||||
Lymph vascular invasion | ||||||||||||
Present | 8 (21.1) | 5 (38.5) | 0.21 | 7 (24.1) | 6 (28.6) | 0.72 | 7 (25.0) | 3 (20.0) | 1.00 | 8 (22.2) | 2 (40.0) | 0.58 |
Absent | 30 (78.9) | 8 (61.5) | 22 (75.9) | 15 (71.4) | 21 (75.0) | 12 (80.0) | 28 (77.8) | 3 (60.0) | ||||
Ki 67 | ||||||||||||
≤ 20% | 11 (23.9) | 1 (7.1) | 0.26 | 8 (22.2) | 3 (13.6) | 0.51 | 9 (26.5) | 1 (6.3) | 0.14 | 9 (22.0) | 0 (0.0) | 0.58 |
> 20% | 35 (76.1) | 13 (92.9) | 28 (77.8) | 19 (86.4) | 25 (73.5) | 15 (93.8) | 32 (78.1) | 6 (100.0) | ||||
Androgen receptor | ||||||||||||
< 10% | 26 (61.9) | 12 (92.3) | 0.05 | 20 (60.6) | 18 (85.7) | 0.07 | 18 (56.3) | 13 (86.7) | 0.05 | 23 (59.0) | 5 (100.0) | 0.14 |
≥ 10% | 16 (38.1) | 1 (7.7) | 13 (39.4) | 3 (14.3) | 14 (43.8) | 2 (13.3) | 16 (41.0) | 0 (0.0) | ||||
Protein expression BCL11A | ||||||||||||
Low: 0–3 | 41 (87.2) | 4 (28.6) | < 0.0001 | 34 (91.9) | 9 (40.9) | < 0.0001 | 31 (88.6) | 7 (43.8) | 0.0001 | 34 (81.0) | 2 (33.3) | 0.03 |
High: 4–8 | 6 (12.8) | 10 (71.4) | 3 (8.1) | 13 (59.1) | 4 (11.4) | 9 (56.3) | 8 (19.1) | 4 (66.7) | ||||
Death | 7 (14.9) | 1 (7.1) | 0.67 | 7 (18.9) | 1 (4.6) | 0.24 | 7 (20.0) | 1 (6.3) | 0.41 | 7 (16.7) | 0 (0.0) | 0.57 |